News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation News Syntheia Signs Definitive Agreement for Call Center Acquisition News Intellistake Technologies Corp. Announces Completion of Change of Business, Name Change and Ticker Symbol Change Digital Transformation News CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification News Wells Fargo Scandal Drove Borrowers to Fintech Lenders, UC Davis Study Suggests News CertiK Cements Institutional Presence After CEO’s Strategic Engagements in Hong Kong